Galectin Reports Q2 Loss of $9.2M, FDA Agreement on Phase 3 Design, and Cash Runway to June 2027
GALT sits 72% above its 52-week low of $2.025.
Summary
Galectin Therapeutics reported a wider Q2 net loss of $9.2 million, driven by a non-cash derivative fair-value charge, and announced FDA agreement on its Phase 3 trial design for belapectin, with protocol submission expected in Q3 2026.
Key Events · Earnings and Guidance · GALT
-
Q2 Net Loss Widens to $9.2M
Net loss applicable to common stockholders was $9.2 million ($0.14/share) for Q2 2026, up from $7.6 million ($0.12/share) in Q2 2025, primarily due to a $3.2 million non-cash charge for change in fair value of derivative liabilities.
-
FDA Agreement on Phase 3 Design
The company reached agreement with the FDA on key elements of the planned Phase 3 trial for belapectin in MASH cirrhosis, including a composite liver outcome primary endpoint, blinded central review, and a single 2 mg/kg LBM dose. Protocol submission is expected in Q3 2026.
-
Cash Runway Through June 2027
As of June 30, 2026, cash and cash equivalents were $13.2 million, with an additional $10 million available under a line of credit from the Chairman. Management believes this is sufficient to fund planned operations through June 2027.
-
Debt-to-Equity Conversion Reiterated
The filing reiterates the previously disclosed conversion of approximately $105.8 million in debt and accrued interest by Chairman Richard Uihlein into 34,376,167 shares of common stock, effective July 31, 2026.
Analysis · GALT · Life Sciences
Galectin Therapeutics reported a Q2 2026 net loss of $9.2 million, wider than the $7.6 million loss a year ago, driven by a $3.2 million non-cash charge from the change in fair value of derivative liabilities. The company also announced it reached agreement with the FDA on the key elements of its Phase 3 trial for belapectin in MASH cirrhosis, including the primary endpoint and dose, with protocol submission expected in Q3 2026. Cash of $13.2 million plus a $10 million available line of credit is expected to fund operations through June 2027. The filing reiterates the previously disclosed $105.8 million debt-to-equity conversion by Chairman Richard Uihlein, but the new financial results and regulatory update are material.
At the time of this filing, GALT was trading at $3.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $356M. The 52-week trading range was $2.03 to $7.13. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.